Covid

Although many countries are in lockdown due to COVID-19, patients can travel to Prague for cancer treatment. More info

New Study Shows Hypofractionated Proton Therapy for Prostate Cancer Is as Effective As Standard Proton Treatment

18.05.2021

Hypofractionated proton therapy for prostate cancer means treating prostate cancer with higher doses of proton therapy over a shorter amount of time.

According to a new study, hypofractionated proton therapy for prostate cancer is as equally effective as standard treatment. The findings were published in the International Journal of Radiation Oncology, Biology, Physics.

Researchers at the University of Pennsylvania and the Roberts Proton Center looked at data on prostate cancer patients treated with 28 doses of proton therapy instead of 44, and found that the rates of cancer control at four years was the same in both groups, with notably low rates of urologic and gastrointestinal effects from the treatment at four-year follow up.

Photon radiation typically uses multiple x-ray beams to attack a tumor target but unfortunately deposits radiation in the normal healthy tissues beyond the target, potentially damaging those tissues as the beam exits the body.

Proton therapy is an FDA-approved treatment that is an alternative radiation treatment. It directs positively charged protons at the tumor target, where they deposit the bulk of the radiation dose, with minimal residual radiation delivered beyond the target, potentially reducing side effects and damage to surrounding tissue.

Read:
Richard’s Prostate Cancer Story

The study looked at data on 184 men who received hypofractionated proton therapy for prostate cancer that was non-metastatic (had not yet spread to other parts of the body). At a follow up of 49 months, 96% of the men were still alive, and with no deaths related to treatment.

The four-year rate of gastrointestinal complications was estimated at 13.6%, almost all of which occurred in the first two years. The cumulative four-year rate of urologic issues was 7.6%. All of these issues resolved within six months of completing treatment.

“This study provides prospective evidence that the higher daily radiation dose delivered in hypofractionated proton therapy does not negatively impact patient quality of life,” stated author Neha Vapiwala, associate professor of Radiation Oncology. “This data can help guide clinicians and patients as they weigh treatment efficacy, tolerability and convenience.”

The authors stated that more research is required to evaluate the differences between hypofractionated radiation with photon and proton radiation.

 

Source:

Grewal, A.S. et al. (2019) Four-year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer. International Journal of Radiation Oncology. doi.org/10.1016/j.ijrobp.2019.05.069.

Contact Us

The Proton Therapy Center in Prague, Czech Republic, is a leading cancer centre dedicated to guiding you through your fight against cancer. Contact us today and our team will get back to you with a detailed response to your needs as soon as possible.

    By sending this form you agree, in accordance with Act 101/2000 Sb. and Regulation 2016/679 (the law on the protection of personal data and GDPR) in the wording of subsequent regulations, to the collection, storage and processing of my personal data according to the Proton Therapy UK Privacy Notice. The PTUK hereby declares that it will collect personal data to the extent necessary to fulfil the fulfilment of the stipulated purpose and process it only in accordance with the purpose for which it was collected.

    Please check your spam email inbox if you do not receive a reply from our team within 2 business days.